Oesophageal Carcinoma Active Not Recruiting Phase 3 Trials for Pembrolizumab (DB09037)

Also known as: Carcinoma of Esophagus / Esophageal Carcinoma / Carcinoma, Esophageal / Esophagus Carcinoma / Carcinoma of oesophagus NOS / Carcinoma of oesophagus / Oesophageal carcinoma NOS / Esophageal carcinoma NOS

IndicationStatusPhase
DBCOND0032513 (Oesophageal Carcinoma)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02564263Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)Treatment
NCT03933449Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyTreatment